2022 WHO Biosimilar Guideline improves access, IGBA says
Under the revised 2022 WHO Biosimilars Guideline, IGBA says regulatory authorities can confidently revaluate biosimilar access requirements.
Source: europeanpharmaceuticalreview.com
Stay updated with breaking news from Embracing Science. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Under the revised 2022 WHO Biosimilars Guideline, IGBA says regulatory authorities can confidently revaluate biosimilar access requirements.